0.397
price down icon0.75%   -0.003
after-market 시간 외 거래: .40 0.003 +0.76%
loading

Nextcure Inc 주식(NXTC)의 최신 뉴스

pulisher
Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India

Mar 25, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia

Mar 17, 2025
pulisher
Mar 13, 2025

NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 10, 2025

2 Net Current Asset Value Stocks to Consider - GuruFocus.com

Mar 10, 2025
pulisher
Mar 08, 2025

Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

NextCure Reports 2024 Financials and Strategic Progress - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times

Mar 07, 2025
pulisher
Mar 06, 2025

NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan

Mar 06, 2025
pulisher
Feb 27, 2025

Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com

Feb 27, 2025
pulisher
Feb 27, 2025

NextCure stock plunges to 52-week low, hits $0.69 - MSN

Feb 27, 2025
pulisher
Feb 12, 2025

NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 10, 2025

Ventia Strengthens Leadership with New Company Secretary Appointment - MSN

Feb 10, 2025
pulisher
Feb 10, 2025

Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance

Feb 10, 2025
pulisher
Feb 06, 2025

Eaton Vance Tax-Managed Diversified Equity Income Fund declares $0.0992 dividend - MSN

Feb 06, 2025
pulisher
Feb 04, 2025

NextCure Faces Potential Delisting from Nasdaq Global Select Market Due to Minimum Bid Requirement Non-Compliance - Defense World

Feb 04, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World

Jan 13, 2025
pulisher
Jan 12, 2025

LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - 조선비즈

Jan 12, 2025
pulisher
Jan 10, 2025

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com

Jan 10, 2025
pulisher
Jan 10, 2025

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

NextCure Advances Cancer Treatment: First Patient Dosed in LNCB74 Phase 1 Trial - StockTitan

Jan 10, 2025
pulisher
Jan 07, 2025

Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews

Jan 07, 2025
pulisher
Dec 25, 2024

NextCure stock hits 52-week low at $0.87 amid market challenges - Investing.com Australia

Dec 25, 2024
pulisher
Dec 25, 2024

NextCure stock hits 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa

Dec 25, 2024
pulisher
Dec 17, 2024

NextCure stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa

Dec 17, 2024
pulisher
Dec 16, 2024

NextCure stock hits 52-week low at $0.99 amid market challenges - Investing.com India

Dec 16, 2024
pulisher
Dec 12, 2024

The Buckle, Inc. Announces Dividend PayoutsKearney, NE — The Buckle, Inc. (NYSE: BKE) disclosed plans for upcoming shareholder dividend payments following the quarterly meeting of its Board of Directors on December 9, 2024. The company greenlighte - Defense World

Dec 12, 2024
pulisher
Dec 11, 2024

FDA clears IND for B7-H4-targeting ADC - BioWorld Online

Dec 11, 2024
pulisher
Dec 10, 2024

NextCure Announces Acceptance of IND Application for LNCB74 - The Manila Times

Dec 10, 2024
pulisher
Dec 10, 2024

NextCure, Inc. Announces Acceptance of IND Application for LNCB74 - Marketscreener.com

Dec 10, 2024
pulisher
Dec 10, 2024

NextCure's Cancer Drug LNCB74 Secures FDA IND Approval for Phase 1 Clinical Trials - StockTitan

Dec 10, 2024
pulisher
Dec 07, 2024

NextCure stock hits 52-week low at $1.00 amid market challenges - Investing.com Australia

Dec 07, 2024
pulisher
Dec 06, 2024

NextCure stock hits 52-week low at $1.00 amid market challenges By Investing.com - Investing.com South Africa

Dec 06, 2024
$67.50
price down icon 1.20%
$73.33
price down icon 0.15%
$31.78
price up icon 1.60%
$18.90
price down icon 7.62%
$92.01
price down icon 1.40%
biotechnology ONC
$264.48
price down icon 3.75%
자본화:     |  볼륨(24시간):